tetanus vaccine News
-
Electrifying Healthcare in Nepal
Last year we shared the stories of two women from the village of Bherichaal-Chepang in Nepal, who had both suffered greatly because their local health post had no electricity. Manisara’s daughter died of tetanus after getting a small cut on her finger, because she was unable to be vaccinated at her local health post. And Rupkali had to travel hours to the nearest town every month to use a ...
-
PFCs, chemicals widespread in environment, linked to lowered immune response to childhood vaccinations
A new study finds that perfluorinated compounds (PFCs), widely used in manufactured products such as non-stick cookware, waterproof clothing, and fast-food packaging, were associated with lowered immune response to vaccinations in children. It is the first study to document how PFCs, which can be transferred to children prenatally (via the mother) and postnatally from exposure in the environment, ...
-
The Dark Side of Your Seasonal Flu Vaccine, and Its Startling Environmental Impact
As the world is embracing the virtues of non-animal derived meats (i.e., made from either plants or lab-grown, cultured protein), non-comestible items relying heavily on animal agriculture need to be rethought too. In our era, animal-derived products must not only keep human health in mind, they must reduce their impact on the environment. Influenza vaccine is one such intensively ...
-
(Viral) Vaccine Manufacturing
It is well accepted that vaccination is one of the most effective ways to prevent diseases. A vaccine helps the body’s immune system to recognize and fight pathogens like bacteria or viruses, which then keeps humans safe from the diseases they cause. Vaccines protect against a range of diseases, including measles, polio, diphtheria, tetanus, meningitis, influenza and cancer. ...
By Nuvonis
-
Ocugen, Inc. Provides an Update on its Investigational New Drug Application with U.S. FDA to Initiate a Phase 3 Clinical Trial Evaluating COVID-19 Vaccine Candidate COVAXIN (BBV152)
MALVERN, Pa., Nov. 26, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing novel therapeutics and vaccines, announced that the U.S. Food and Drug Administration (FDA) has issued a clinical hold on the Company’s Investigational New Drug application (IND) to evaluate the COVID-19 vaccine candidate, BBV152, ...
By Ocugen, Inc.
-
COVAXIN (BBV152) Booster Dose Study Demonstrates Robust Immune Responses and Long-Term Safety
Participants receiving a booster dose six months after second dose of COVAXIN™ saw significant increase (>10-fold across Alpha, Beta, Delta and Delta Plus variants) in neutralizing titers compared to baseline at six months Persistence of memory B and T cell immune responses at six months post second dose Pronounced SARS-CoV-2-specific T cell response to COVAXIN™ before and ...
By Ocugen, Inc.
-
New Data Suggest COVAXIN (BBV152) Vaccine Candidate Generates Robust Immune Memory to COVID-19 and Variants of Concern for At Least Six Months After Vaccination
Level of vaccine-induced spike and nucleoprotein antibodies titers demonstrated to be comparable to that following natural infection Immune memory against conserved nucleoprotein may provide an added advantage over spike-only responses Memory T and B cells persisted for at least 6 months post vaccination Data suggest COVAXIN™ (BBV152) may provide protection against current and future ...
By Ocugen, Inc.
-
Ocugen Partner, Bharat Biotech, Announces Positive Immunogenicity and Safety Data from COVAXIN (BBV152), COVID-19 Candidate Vaccine, in Children 2 – 18 YEARS
COVAXIN™ whole virus inactivated vaccine generated broad antibody response comparable to those seen in a large phase 3 trial in adults 18+ Adverse events were primarily mild, and no serious adverse events (SAEs) were noted Immunobridging trial demonstrated safety, reactogenicity and immunogenicity of COVAXIN™ in children from 2 years old and up No cases of myocarditis or blood ...
By Ocugen, Inc.
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you